Drug Trial Radar · NCT06731868
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jan 14, 2025
Primary completion
Oct 31, 2025
Study completion Oct 31, 2025
Sponsor
- Lead sponsor
- Luye Pharma Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group trial to evaluate the safety, tolerability, preliminary efficacy and PK characteristics of multiple doses of LPM3770164 sustained-release tablets in TD patients.
Conditions
- Tardive Dyskinesia (TD)
Interventions
LPM3770164 sustained release tablet 5 mgDrug
LPM3770164 sustained release tablet once daily oral dosage at 5 mg for 6 weeks
LPM3770164 sustained release tablet 10 mgDrug
LPM3770164 sustained release tablet once daily oral dosage at 10 mg for 6 weeks.
LPM3770164 sustained release tablet 20 mgDrug
LPM3770164 sustained release tablet once daily oral dosage at 20 mg for 6 weeks.
LPM3770164 sustained release tablet simulantDrug
LPM3770164 sustained release tablet simulant once daily oral for 6 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse eventTime frame: From baseline to Week 8
- Change in Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total ScoreTime frame: From baseline to Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.